Manual
Each tablet contains:
- active substance: ipidacrine hydrochloride 20 mg;
- excipients: lactose monohydrate, potato starch, calcium stearate.
As part of complex therapy:
- diseases of the peripheral nervous system (neuritis, polyneuritis, polyneuropathy, polyradiculoneuropathy, myasthenia gravis and myasthenic syndrome of various etiologies);
- diseases of the central nervous system: bulbar paralysis and paresis;
- recovery period for organic lesions of the central nervous system, accompanied by motor disorders;
- demyelinating diseases of the nervous system (including multiple sclerosis);
- memory impairments of various origins (Alzheimer’s disease, other forms of senile dementia);
- intestinal atony.
For oral administration. The tablet must be swallowed with water. Doses and duration of treatment are determined individually depending on the severity of the disease. Diseases of the peripheral nervous system, myasthenia gravis and myasthenic syndrome: 10-20 mg orally 1-3 times a day. The course of treatment is from one to two months. If necessary, the course of treatment can be repeated several times with a break between courses of 1-2 months. To prevent myasthenic crises in severe disorders of neuromuscular conduction, 15-30 mg (1-2 ml of Neurodaks 15 mg/ml solution for injection) is administered parenterally for a short time. Then treatment is continued with the tablet form of the drug and the dose can be increased to 20-40 mg 5-6 times a day. Memory impairments of various origins (Alzheimer’s disease and other forms of senile dementia): The dose and duration of treatment are determined individually. The maximum daily dose can sometimes reach 200 mg. The course of treatment is from one month to one year. Treatment and prevention of intestinal atony: 20 mg 2-3 times a day for 1-2 weeks. Special groups of patients.